Sofia Ernestam

2.2k total citations
44 papers, 1.6k citations indexed

About

Sofia Ernestam is a scholar working on Rheumatology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Sofia Ernestam has authored 44 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Rheumatology, 13 papers in Hematology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Sofia Ernestam's work include Rheumatoid Arthritis Research and Therapies (34 papers), Autoimmune and Inflammatory Disorders Research (13 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Sofia Ernestam is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (34 papers), Autoimmune and Inflammatory Disorders Research (13 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Sofia Ernestam collaborates with scholars based in Sweden, United States and Iceland. Sofia Ernestam's co-authors include Ronald van Vollenhoven, Johan Bratt, Ingemar F. Petersson, Pierre Geborek, Kristina Forslind, Staffan Lindblad, Saedís Saevarsdóttir, Lars Klareskog, Kristina Albertsson and Martin Neovius and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and JAMA Internal Medicine.

In The Last Decade

Sofia Ernestam

41 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sofia Ernestam Sweden	22	1.2k	452	326	319	219	44	1.6k
A. Gerards Netherlands	14	1.7k 1.4×	749 1.7×	336 1.0×	383 1.2×	268 1.2×	29	2.0k
J.H.L.M. van Groenendael Netherlands	16	1.9k 1.5×	744 1.6×	324 1.0×	406 1.3×	282 1.3×	22	2.1k
L. Settas Greece	12	1.5k 1.2×	678 1.5×	434 1.3×	283 0.9×	226 1.0×	20	2.0k
Marie Sanda United States	12	1.4k 1.2×	615 1.4×	335 1.0×	262 0.8×	180 0.8×	15	1.9k
Siegfried Wassenberg Germany	21	1.8k 1.5×	726 1.6×	716 2.2×	186 0.6×	173 0.8×	61	2.2k
J-C Becker United States	13	1.7k 1.4×	745 1.6×	484 1.5×	431 1.4×	365 1.7×	17	2.1k
Grace S. Park United States	19	860 0.7×	221 0.5×	409 1.3×	145 0.5×	361 1.6×	31	1.4k
Beverley Harrison United Kingdom	20	1.5k 1.2×	479 1.1×	397 1.2×	157 0.5×	248 1.1×	29	1.9k
M Haga Canada	8	1.2k 0.9×	277 0.6×	255 0.8×	188 0.6×	272 1.2×	10	1.6k
Martina Biggioggero Italy	23	1.1k 0.9×	362 0.8×	555 1.7×	205 0.6×	118 0.5×	69	1.7k

Countries citing papers authored by Sofia Ernestam

Since Specialization

Citations

This map shows the geographic impact of Sofia Ernestam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofia Ernestam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofia Ernestam more than expected).

Fields of papers citing papers by Sofia Ernestam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofia Ernestam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofia Ernestam. The network helps show where Sofia Ernestam may publish in the future.

Co-authorship network of co-authors of Sofia Ernestam

This figure shows the co-authorship network connecting the top 25 collaborators of Sofia Ernestam. A scholar is included among the top collaborators of Sofia Ernestam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofia Ernestam. Sofia Ernestam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hedström, Anna Karin, Lars Klareskog, Daniela Di Giuseppe, et al.. (2022). Neither low social support nor low decision latitude at work is associated with disease remission among patients with rheumatoid arthritis: results from the Swedish EIRA study. Arthritis Research & Therapy. 24(1). 203–203.

Askling, Johan, Xia Jiang, Sofia Ernestam, et al.. (2021). Social stressors and risk of rheumatoid arthritis and their relationship to known modifiable risk factors: results from the Swedish EIRA study. Scandinavian Journal of Rheumatology. 50(3). 178–182. 1 indexed citations

Hambardzumyan, Karen, Per Marits, Nancy Vivar, et al.. (2019). Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population. Scandinavian Journal of Rheumatology. 48(5). 362–366. 29 indexed citations

Essén, Anna, et al.. (2016). Value-Based Health Care for Chronic Care: Aligning Outcomes Measurement with the Patient Perspective. Quality Management in Health Care. 25(4). 203–212. 6 indexed citations

Lindblad, Staffan, et al.. (2016). Creating a culture of health: evolving healthcare systems and patient engagement. QJM. 110(3). hcw188–hcw188. 35 indexed citations

Kastbom, Alf, Kristina Forslind, Sofia Ernestam, et al.. (2014). Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Annals of the Rheumatic Diseases. 75(2). 356–361. 28 indexed citations

Eriksson, Jonas, Johan Karlsson, Johan Bratt, et al.. (2014). Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Annals of the Rheumatic Diseases. 74(6). 1094–1101. 43 indexed citations

Saevarsdóttir, Saedís, Pierre Geborek, Ingemar F. Petersson, et al.. (2014). Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Annals of the Rheumatic Diseases. 74(8). 1509–1514. 54 indexed citations

Eriksson, Jonas, Martin Neovius, Johan Bratt, et al.. (2013). Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis. JAMA Internal Medicine. 173(15). 1407–1407. 29 indexed citations

10.

Karlsson, Johan, Martin Neovius, Jan‐Åke Nilsson, et al.. (2012). Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Annals of the Rheumatic Diseases. 72(12). 1927–1933. 21 indexed citations

11.

Vollenhoven, Ronald van, Pierre Geborek, Kristina Forslind, et al.. (2012). Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. The Lancet. 379(9827). 1712–1720. 157 indexed citations

12.

Saevarsdóttir, Saedís, Kristina Forslind, Kristina Albertsson, et al.. (2011). In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Annals of the Rheumatic Diseases. 71(2). 186–191. 75 indexed citations

13.

Saevarsdóttir, Saedís, Helena Wallin, Maria Seddighzadeh, et al.. (2010). Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Annals of the Rheumatic Diseases. 70(3). 469–475. 149 indexed citations

14.

Vollenhoven, Ronald van, Sofia Ernestam, P. Geborek, et al.. (2009). Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. The Lancet. 374(9688). 459–466. 224 indexed citations

15.

Sundberg, Erik, Cecilia Grundtman, Erik af Klint, et al.. (2008). Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study. Arthritis Research & Therapy. 10(2). R33–R33. 31 indexed citations

16.

Kopp, S, et al.. (2006). Interleukin‐1β influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis. Scandinavian Journal of Rheumatology. 35(3). 182–188. 11 indexed citations

17.

Catrina, Anca I., Erik af Klint, Sofia Ernestam, et al.. (2005). Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis & Rheumatism. 54(1). 76–81. 86 indexed citations

18.

Kopp, Sigvard, et al.. (2005). Reduction of Temporomandibular Joint Pain after Treatment with a Combination of Methotrexate and Infliximab Is Associated with Changes in Synovial Fluid and Plasma Cytokines in Rheumatoid Arthritis. Cells Tissues Organs. 180(1). 22–30. 26 indexed citations

19.

Ernestam, Sofia, Erik af Klint, Anca I. Catrina, et al.. (2005). Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.. Arthritis Research & Therapy. 8(1). R18–R18. 22 indexed citations

20.

Vollenhoven, Ronald van, et al.. (2003). Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Research & Therapy. 5(6). R347–51. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact